logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
RVMD
Revolution Medicines, Inc.
189.76
2 x 176.55
2 x 205.50
bid
ask
+
1.64
0.87%
2 @ 04:12 PM
189.76 +0.00 (0.00%)
Ytd138.24%
1y298.49%
184.37
day range
193.46
47.50
52 week range
221.15
Open186.01Prev Close188.12Low184.37High193.46Mkt Cap40.67B
Vol2.21MAvg Vol1.93MEPS-8.87P/EN/AForward P/E-32.55
Beta1.40Short Ratio5.53Inst. Own101.25%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0450-d Avg203.48200-d Avg148.371yr Est259.14

RVMD News

Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%
benzinga.com
Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%

Stocks slip as Gulf tanker attacks lift Brent above $105 and the 10-year yield nears 5.35%; small ca
benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor
benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

Here Are Monday’s Top Wall Street Analyst Research Calls: Align Technology, AutoNation, Estee Lauder, Harley-Davidson, HubSpot, Microsoft, Mosaic, Ryder System, Wells Fargo & Company, and More
247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Align Technology, AutoNation, Estee Lauder

Wall Street kicked off the first full week of Q4 2026 with a flurry of bold analyst moves, including
benzinga.com
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical T

Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to d

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
globenewswire.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (da

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a
benzinga.com
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target

Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with
benzinga.com
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
benzinga.com
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an

benzinga.com
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy

benzinga.com
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Ta

Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with

benzinga.com
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and rais

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
benzinga.com
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an
benzinga.com
Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial

Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to d

Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
benzinga.com
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $40

Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can pus

SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
benzinga.com
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerousl

Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
benzinga.com
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

benzinga.com
UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the pr
benzinga.com
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
benzinga.com
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 pre

Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
benzinga.com
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms is

Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
benzinga.com
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakth

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90%
benzinga.com
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and

benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor
benzinga.com
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an
benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

Top 3 Health Care Stocks That May Keep You Up At Night In Q3
benzinga.com
Top 3 Health Care Stocks That May Keep You Up At Night In Q3

As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m
benzinga.com
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe
benzinga.com
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
benzinga.com
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug
benzinga.com
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials sho
benzinga.com
Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perfor
benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a
benzinga.com
BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations U

Companies also enter a separate regional rights agreement granting BeOne exclusive development and c

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years
benzinga.com
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an
benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor
benzinga.com
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an
benzinga.com
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe
benzinga.com
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra
benzinga.com
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

benzinga.com
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the a
benzinga.com
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an
benzinga.com
Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Tr

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targete
benzinga.com
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

4 Health Care Stocks Whale Activity In Today’s Session
benzinga.com
4 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w
benzinga.com
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra

9 Health Care Stocks Whale Activity In Today’s Session
benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w
benzinga.com
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $195 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a
benzinga.com
Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Mizuho analyst Joseph Catanzaro maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an